Increased vascular MMP-9 in mice lacking RNF213: Moyamoya disease susceptibility gene

NeuroReport

Volumn 25, Issue 18, 2014, Pages 1442-1446

  Sonobe, Shinya ^a   Fujimura, Miki ^a   Niizuma, Kuniyasu ^a   Fujimura, Taku ^a   Furudate, Sadanori ^a   Nishijima, Yasuo ^a   Kure, Shigeo ^a   Tominaga, Teiji ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Constrictive remodeling; Homologous recombination; Knockout mice; Matrix metalloproteinase 9; Moyamoya disease; RNF213

Indexed keywords

GELATINASE B; MMP9 PROTEIN, MOUSE; RNF213 PROTEIN, MOUSE; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL WALL; CAROTID ARTERY LIGATION; COMMON CAROTID ARTERY; CONTROLLED STUDY; FEMALE; GENE; GENETIC SUSCEPTIBILITY; HISTOPATHOLOGY; HYPERPLASIA; KNOCKOUT MOUSE; MALE; MOUSE; MOYAMOYA DISEASE; NONHUMAN; PROTEIN EXPRESSION; RNF213 GENE; WILD TYPE; ANIMAL; ARTERY; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; ENZYMOLOGY; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; ARTERIES; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOYAMOYA DISEASE; REAL-TIME POLYMERASE CHAIN REACTION; UBIQUITIN-PROTEIN LIGASES;

EID: 84915737367     PISSN: 09594965     EISSN: 1473558X     Source Type: Journal    
DOI: 10.1097/WNR.0000000000000289     Document Type: Article

References (20)

1. Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle ofWillis; Health Labour Sciences Research Grant for Research on Measures for Infractable Diseases. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo) 2012; 52:245-266
2. Suzuki J, Takaku A. Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 1969; 20:288-299
3. Oka K, Yamashita M, Sadoshima S, Tanaka K. Cerebral haemorrhage in Moyamoya disease at autopsy. Virchows Arch A Pathol Anat Histol 1981; 392:247-261
4. Kaku Y, Morioka M, Ohmori Y, Kawano T, Kai Y, Fukuoka H, et al. Outerdiameter narrowing of the internal carotid and middle cerebral arteries in moyamoya disease detected on 3D constructive interference in steady-state MR image: is arterial constrictive remodeling a major pathogenesis? Acta Neurochir (Wien) 2012; 154:2151-2157
5. Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, Kikuchi A, et al. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet 2011; 56:34-40
6. Liu W, Morito D, Takashima S, Mineharu Y, Kobayashi H, Hitomi T, et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One 2011; 6:e22542
7. Wu Z, Jiang H, Zhang L, Xu X, Zhang X, Kang Z, et al. Molecular analysis of RNF213 gene for moyamoya disease in the Chinese Han population. PLoS One 2012; 7:e48179
8. Miyatake S, Miyake N, Touho H, Nishimura-Tadaki A, Kondo Y, Okada I, et al. Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease. Neurology 2012; 78:803-810
9. Sonobe S, Fujimura M, Niizuma K, Nishijima Y, Ito A, Shimizu H, et al. Temporal profile of the vascular anatomy evaluated by 9.4-T magnetic resonance angiography and histopathological analysis in mice lacking RNF213: a susceptibility gene for moyamoya disease. Brain Res 2014; 1552:64-71
10. Fujimura M, Sonobe S, Nishijima Y, Niizuma K, Sakata H, Kure S, Tominaga T. Genetics and biomarkers of Moyamoya disease: significance of RNF213 as a susceptibility gene. J Stroke 2014; 16:65-72
11. Godin D, Ivan E, Johnson C, Magid R, Galis ZS. Remodeling of carotid artery is associated with increased expression of matrix metalloproteinases in mouse blood flow cessation model. Circulation 2000; 102:2861-2866
12. Kumar A, Lindner V. Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. Arterioscler Thromb Vasc Biol 1997; 17:2238-2244
13. Kambayashi Y, Fujimura T, Aiba S. Comparison of immunosuppressive and immunomodulatory cells in keratoacanthoma and cutaneous squamous cell carcinoma. Acta Derm Venereol 2013; 93:663-668
14. Fujimura T, Kambayashi Y, Furudate S, Kakizaki A, Aiba S. Immunomodulatory effect of bisphosphonate risedronate sodium on CD163 + arginase 1 + M2 macrophages: the development of a possible supportive therapy for angiosarcoma. Clin Dev Immunol 2013; 2013:325412
15. Gasche Y, Fujimura M, Morita-Fujimura Y, Copin JC, Kawase M, Massengale J, Chan PH. Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfunction. J Cereb Blood Flow Metab 1999; 19:1020-1028
16. Fujimura M, Watanabe M, Narisawa A, Shimizu H, Tominaga T. Increased expression of serum matrix metalloproteinase-9 in patients with moyamoya disease. Surg Neurol 2009; 72:476-480, discussion 480
17. Kang HS, Kim JH, Phi JH, Kim YY, Kim JE, Wang KC, et al. Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease. J Neurol Neurosurg Psychiatry 2010; 81:673-678
18. Fujimura M, Gasche Y, Morita-Fujimura Y, Massengale J, Kawase M, Chan PH. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res 1999; 842:92-100
19. Huang CY, Fujimura M, Noshita N, Chang YY, Chan PH. SOD1 downregulates NF-kappaB and c-Myc expression in mice after transient focal cerebral ischemia. J Cereb Blood Flow Metab 2001; 21:163-173
20. Hitomi T, Habu T, Kobayashi H, Okuda H, Harada KH, Osafune K, et al. The moyamoya disease susceptibility variant RNF213 R4810K (rs112735431) induces genomic instability by mitotic abnormality. Biochem Biophys Res Commun 2013; 439:419-426.